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Radiation-induced fibrosis is a delayed complication of 
radiotherapy often associated with chronic inflammatory 
process and macrophage infiltration. Nowadays, macrophages 
are suggested to be important cellular contributors to 
fibrogenic process, but their implication in the context of RIF 
is not well known. 
To investigate the role of macrophages in RIF we have used a 
classical experimental model of lung fibrosis developed in 
C57Bl/6 mice after 16Gy thorax-IR. We then profiled both 
alveolar macrophages (AM) and interstitial macrophages (IM) 
during the various steps of the fibrogenic process. 
We confirmed the fact that total lung irradiation at 16Gy (IR) 
induces an interstitial fibrosis associated with delayed 
recruitment of pulmonary macrophages. We found a transient 
depletion of AM associated with cytokine secretion during the 
acute post-IR phase (15 days), followed by an active 
repopulation and an enhanced number of AM during the late 
post-IR phase (20 weeks). Interestingly, AM were mostly 
recruited from the bone marrow and exhibit a hybrid 
polarization (M1/M2) associated with up-regulation of Th1 
and Th2 cytokines. The number of M2-polarized IM 
significantly increased during the late time points after 
irradiation and a down-regulation of Th1 cytokine was 
measured in tissue lysate. These results suggest a differential 
contribution of hybrid AM vsM2-IM to fibrogenesis. 
Interestingly, in contrast to activated hybrid AM, activated 
M2-IM were able to induce fibroblast activation in vitro 
mediated by an enhanced TGF-β1 expression suggesting a 
profibrotic role of M2-IM. Specific depletion of hybrid AM 
using intranasal administration of clodrosome increased 
radiation-induced fibrosis score and enhanced M2-IM 
infiltration suggesting a protective role of hybrid AM. 
These present study shows a dual and opposite contribution 
of alevolar versus intertitial macrophages in radiation-
induced fibrosis and identify M2-IM as a potential therapeutic 
target to treat radiation-induced fibrosis. 
 
Symposium: Regional nodal irradiation for breast cancer  
 
 
SP-0015  
The axilla- less surgery, more radiotherapy? 
M.I. Algara López
1Hospital de la Esperança, Radiation Oncology, Barcelona, 
Spain 
1 
 
Irradiation of lymph node areas in breast cancer patients, 
especially in early stages of the disease is a controversial 
topic. The recommendation to irradiate lymph nodes is 
clearly indicated in patients with more than three involved 
nodes. In these cases, after standard lymphadenectomy, the 
volumes to irradiate include supraclavicular fossa and axillary 
level III nodes. Until a few years ago, irradiation of axillary 
levels I and II, are reserved for cases of very large axillary 
involvement, or in patients whom lymphadenectomy was 
insufficient (less than 10 lymph nodes resected). However, 
when only 1 to 3 nodes are involved, there is no unanimity on 
the radiotherapy recommendations, despite several studies 
having show clearly a disease free survival improvement in 
irradiated patients. The Canadian trial NCIC-CTG MA20, 
including high risk patients, most of them with 1 to 3 
involved nodes, showed that local irradiation with regional 
lymph node irradiation improved disease-free survival, both 
loco-regional and distant disease control. The EORTC trial 
also demonstrates the same findings: regional irradiation in 
breast cancer patients improve even the overall survival. 
Therefore the current trend, described in international 
guidelines, lymph node irradiation is recommended for all 
patients regardless of the number of positive nodes. 
Nevertheless, the therapeutic value of axillary 
lymphadenectomy has been questioned for a long time. The 
ACOSOG Z0011 study results have caused clinical practice 
changes since many axillary dissections are being avoided. 
Even several clinical practice guidelines, including prestigious 
ones such as those of National Comprehensive Cancer 
Network, don’t recommend lymphadenectomy. The ACOSOG 
Z0011 does not exactly describe the irradiated nodal volumes 
exactly. Therefore, the nodal volumes to include in the 
irradiation treatment of early stages of breast cancer remains 
under discussion, especially without axillary 
lymphadenectomy despite involvement of sentinel lymph 
nodes. In most cases, breast irradiation with tangent fields 
implies certain “incidental” of axillary level I, and also in 
some cases the level II. For this reason, some groups have 
decided to avoid intentional irradiation of these axillary 
areas, while others advocate to irradiate them intentionally, 
without clear evidence to do that. The AMAROS trial 
demonstrated that lymph node radiotherapy obtains the same 
results as axillary dissection in node-positive patients without 
primary systemic treatment, with less morbidity. Therefore, 
it is possible to replace the surgery with radiation. The 
current situation is that some groups decide to irradiate 
lymph node in cases with positive sentinel node without 
lymphadenectomy and other groups in these cases do not 
treat the lymph node, and accept that some incidental 
irradiation will arrive by tangential fields. But, we do not 
know which patients, with positive nodes, do not require 
lymph node irradiation. It is possible that in patients with low 
axillary involvement intentional irradiation would not be 
necessary. In order to demonstrate this hypothesis, we have 
started the OPTYMAL trial (www.clinicaltrials.gov 
/ct2/show/NCT02335957?term=osna&rank=7) to investigate 
the non-inferiority of incidental versus intentional irradiation 
of axillary nodes in patients with axillary involvement of 250-
15000 copies/uL with One Step Nucleic Acid Amplification 
method (OSNA). We decided to use this method to unify the 
pathological reports. This international multicenter trial must 
help us to elucidate the necessity of node area irradiation by 
combining with reliable information about the tumor load 
involvement in axillary nodes. 
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Locoregional radiation therapy (RT) improves locoregional 
control and survival for patients treated with breast 
conserving therapy and for patients after mastectomy with 
risk factors including involved axillary lymph nodes. In the 
past, however, this treatment could be linked to an increased 
risk for late cardiovascular morbidity and mortality as a 
result of cardiac exposure to radiation. This was especially 
the case for the treatment of the internal mammary lymph 
node target volume, for which this was abandoned by many 
